Literature DB >> 12234272

A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation.

Elias David-Neto1, Lilian Pereira Araujo, Cristiane Feres Alves, Nairo Sumita, Pascoalina Romano, Elisa Midori Yagyu, William Carlos Nahas, Luiz Estevam Ianhez.   

Abstract

The complete area under the time-concentration curve (AUC) is considered the gold standard for cyclosporin A (CsA) monitoring, particularly in pediatric kidney graft recipients who have great absorption and drug clearance variability. However, complete AUC is time-consuming and expensive. For this reason, we retrospectively reviewed 131 complete 4-h AUC (AUC0-4) performed in 34 children (mean age 10.6 +/- 2 yr) in order to construct an equation to calculate AUC0-4. The median time after transplantation was 540 (range: 247-1,358) days. Multiple regression analysis was performed either with a single variable or with a combination of two variables. CsA blood concentration at the second hour after the oral morning dose (C2) was the best predictor of AUC0-4, where AUC0-4 = 424 + (2.65 x C2), R2 = 0.81, p < 0.001. Only the combination of C1 and C2 offered mathematical improvement over the C2 equation. The same analysis was made for pharmacokinetic curves performed earlier than 6 months (79 +/- 55 days, range 8-169 days) and after 1 yr of transplantation. In both time-periods, C2 was the best parameter to use to calculate AUC0-4. The equations obtained during these two time-periods were very close to the one for the whole population. Our data shows that C2 can be safely used to estimate AUC0-4. However, for values above 4,000 ng/h/mL, the formula overestimates the trapezoidal AUC0-4. The C2 equation simplifies the CsA monitoring as a result of its high predictive value and clinical feasibility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234272     DOI: 10.1034/j.1399-3046.2002.02019.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  6 in total

1.  Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome.

Authors:  Katsumi Ushijima; Osamu Uemura; Takuji Yamada
Journal:  Eur J Pediatr       Date:  2011-11-26       Impact factor: 3.183

2.  Cyclosporine A monitoring--how to account for twice and three times daily dosing.

Authors:  Samuel Fanta; Janne T Backman; Paula Seikku; Christer Holmberg; Kalle Hoppu
Journal:  Pediatr Nephrol       Date:  2005-03-17       Impact factor: 3.714

Review 3.  IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome.

Authors:  Agnes Trautmann; Olivia Boyer; Elisabeth Hodson; Arvind Bagga; Debbie S Gipson; Susan Samuel; Jack Wetzels; Khalid Alhasan; Sushmita Banerjee; Rajendra Bhimma; Melvin Bonilla-Felix; Francisco Cano; Martin Christian; Deirdre Hahn; Hee Gyung Kang; Koichi Nakanishi; Hesham Safouh; Howard Trachtman; Hong Xu; Wendy Cook; Marina Vivarelli; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2022-10-21       Impact factor: 3.651

4.  Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation.

Authors:  Elias David-Neto; Lilian Monteiro Pereira Araujo; Nairo Massakazu Sumita; Maria Elizabeth Mendes; Maria Cristina Ribeiro Castro; Cristiane Feres Alves; Erica Kakehashi; Paschoalina Romano; Elisa Midori Yagyu; Margaret Queiroga; William Carlos Nahas; Luiz Estevam Ianhez
Journal:  Pediatr Nephrol       Date:  2003-02-22       Impact factor: 3.714

5.  Absorption phase cyclosporine (C(2h)) monitoring in the first weeks after pediatric renal transplantation.

Authors:  Udo Vester; Birgitta Kranz; Gisela Offner; Silvio Nadalin; Andreas Paul; Christoph E Broelsch; Peter E Hoyer
Journal:  Pediatr Nephrol       Date:  2004-11       Impact factor: 3.714

Review 6.  Current management issues of immediate postoperative care in pediatric kidney transplantation.

Authors:  Fabio Cesar Miranda Torricelli; Andreia Watanabe; Elias David-Neto; William Carlos Nahas
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.